

Galapagos achieves milestone payments for rheumatoid arthritis alliance

Mechelen, Belgium; 14 January 2009 – Galapagos NV (Euronext: GLPG) announced today achievement of multiple milestones under its alliance with Janssen Pharmaceutica NV ('Janssen'). Through the achievement of the milestone payments announced today Galapagos will receive a total of €3.75 million.

In October 2007, Galapagos announced an alliance agreement with Janssen providing Janssen with option rights to acquire worldwide, commercial licenses to novel small-molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis (RA) therapeutic targets. The milestones announced today relate to achievement of Proof of Principle for compounds developed against Galapagos targets. The compounds demonstrated a reduction of an inflammatory disease biomarker in inflamed joint tissue cultured from collagen-induced arthritic mice. Showing a reduction in such a disease marker is an important step in the development of a new drug, indicating that the potential drug can have an impact on slowing or reversing disease.

About Galapagos

Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as ADMET products to select compounds. Galapagos currently employs 460 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More information about Galapagos can be found at www.glpj.com.

CONTACT

Galapagos NV
Graham Dixon, PhD
Senior Vice President Drug Discovery
+32 473 86 87 51
ir@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.